image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 37.74
-0.343 %
$ 2.08 B
Market Cap
35.27
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SUPN stock under the worst case scenario is HIDDEN Compared to the current market price of 37.7 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SUPN stock under the base case scenario is HIDDEN Compared to the current market price of 37.7 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one SUPN stock under the best case scenario is HIDDEN Compared to the current market price of 37.7 USD, Supernus Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
608 M REVENUE
-8.95%
-5.27 M OPERATING INCOME
-7.83%
1.32 M NET INCOME
-97.83%
111 M OPERATING CASH FLOW
-4.91%
269 M INVESTING CASH FLOW
224.03%
-398 M FINANCING CASH FLOW
-3697.65%
176 M REVENUE
4.37%
40.8 M OPERATING INCOME
124.25%
38.5 M NET INCOME
93.30%
53.5 M OPERATING CASH FLOW
50.24%
-77 M INVESTING CASH FLOW
-58.48%
3.08 M FINANCING CASH FLOW
85.46%
Balance Sheet Supernus Pharmaceuticals, Inc.
image
Current Assets 493 M
Cash & Short-Term Investments 255 M
Receivables 144 M
Other Current Assets 94.1 M
Non-Current Assets 785 M
Long-Term Investments 16.6 M
PP&E 42.5 M
Other Non-Current Assets 725 M
Current Liabilities 290 M
Accounts Payable 1.96 M
Short-Term Debt 8.33 M
Other Current Liabilities 280 M
Non-Current Liabilities 66 M
Long-Term Debt 33.2 M
Other Non-Current Liabilities 32.8 M
EFFICIENCY
Earnings Waterfall Supernus Pharmaceuticals, Inc.
image
Revenue 608 M
Cost Of Revenue 83.8 M
Gross Profit 524 M
Operating Expenses 529 M
Operating Income -5.27 M
Other Expenses -6.58 M
Net Income 1.32 M
RATIOS
86.21% GROSS MARGIN
86.21%
-0.87% OPERATING MARGIN
-0.87%
0.22% NET MARGIN
0.22%
0.14% ROE
0.14%
0.10% ROA
0.10%
-0.27% ROIC
-0.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Supernus Pharmaceuticals, Inc.
image
Net Income 1.32 M
Depreciation & Amortization 84.9 M
Capital Expenditures -551 K
Stock-Based Compensation 26.8 M
Change in Working Capital -9.14 M
Others 35.3 M
Free Cash Flow 111 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Supernus Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for SUPN of $38.8 , with forecasts ranging from a low of $36 to a high of $41 .
SUPN Lowest Price Target Wall Street Target
36 USD -4.61%
SUPN Average Price Target Wall Street Target
38.8 USD 2.68%
SUPN Highest Price Target Wall Street Target
41 USD 8.64%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Supernus Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
11.8 M USD 6
3-6 MONTHS
313 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
3.35 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 03, 2024
Sell 467 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 12745
36.68 USD
2 months ago
Nov 11, 2024
Sell 388 K USD
NEWHALL CHARLES W III
Director
- 10700
36.24 USD
2 months ago
Nov 08, 2024
Sell 316 K USD
Hudson Frederick M.
Director
- 8722
36.28 USD
2 months ago
Nov 08, 2024
Sell 392 K USD
GEMAYEL GEORGES
Director
- 10787
36.3 USD
2 months ago
Nov 08, 2024
Sell 4.54 M USD
Khattar Jack A.
President, CEO
- 125000
36.29 USD
2 months ago
Nov 07, 2024
Sell 555 K USD
Mottola Frank
SVP, Quality, GMP, Ops, IT
- 15000
36.98 USD
2 months ago
Nov 07, 2024
Sell 520 K USD
GEMAYEL GEORGES
Director
- 14213
36.62 USD
2 months ago
Nov 07, 2024
Sell 4.58 M USD
Khattar Jack A.
President, CEO
- 125000
36.68 USD
4 months ago
Sep 13, 2024
Sell 313 K USD
GEMAYEL GEORGES
Director
- 10000
31.33 USD
10 months ago
Mar 21, 2024
Sell 512 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 14491
35.31 USD
10 months ago
Mar 20, 2024
Sell 14.1 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 400
35.31 USD
10 months ago
Mar 19, 2024
Sell 437 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 12364
35.31 USD
10 months ago
Mar 13, 2024
Sell 895 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 26250
34.1 USD
10 months ago
Mar 13, 2024
Sell 1.21 M USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 36116
33.48 USD
10 months ago
Mar 12, 2024
Sell 128 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3884
32.99 USD
10 months ago
Feb 26, 2024
Sell 151 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 5000
30.21 USD
1 year ago
Jan 10, 2024
Sell 223 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 8000
27.91 USD
1 year ago
Nov 16, 2023
Sell 70 K USD
NEWHALL CHARLES W III
Director
- 2500
28.01 USD
1 year ago
Nov 15, 2023
Sell 111 K USD
Hudson Frederick M.
Director
- 3882
28.5 USD
1 year ago
Nov 15, 2023
Sell 149 K USD
Hudson Frederick M.
Director
- 5211
28.5 USD
1 year ago
Nov 14, 2023
Sell 31.2 K USD
Mottola Frank
SVP, Quality, GMP, Ops, IT
- 1110
28.13 USD
1 year ago
Aug 30, 2023
Sell 259 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 8100
32 USD
1 year ago
Aug 25, 2023
Sell 162 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5135
31.59 USD
1 year ago
Mar 14, 2023
Sell 172 K USD
Mottola Frank
Sr VP, Quality, GMP Oper. & IT
- 4780
35.988 USD
1 year ago
Feb 03, 2023
Sell 8.4 K USD
Khattar Jack A.
President, CEO
- 200
42.02 USD
1 year ago
Feb 02, 2023
Sell 569 K USD
Khattar Jack A.
President, CEO
- 13532
42.055 USD
1 year ago
Feb 01, 2023
Sell 12.6 K USD
Khattar Jack A.
President, CEO
- 300
42.0067 USD
1 year ago
Jan 31, 2023
Sell 41 K USD
Khattar Jack A.
President, CEO
- 976
42.0106 USD
2 years ago
Jan 18, 2023
Sell 199 K USD
Khattar Jack A.
President, CEO
- 4936
40.3959 USD
2 years ago
Jan 17, 2023
Sell 193 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 4826
39.9167 USD
2 years ago
Jan 17, 2023
Sell 1.02 M USD
Khattar Jack A.
President, CEO
- 25446
40.0349 USD
2 years ago
Jan 06, 2023
Sell 6.94 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 174
39.9 USD
2 years ago
Dec 21, 2022
Sell 433 K USD
Khattar Jack A.
President, CEO
- 11354
38.1425 USD
2 years ago
Dec 20, 2022
Sell 152 K USD
Khattar Jack A.
President, CEO
- 4006
38.0222 USD
2 years ago
Dec 01, 2022
Sell 187 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 5000
37.4832 USD
2 years ago
Nov 25, 2022
Sell 392 K USD
Khattar Jack A.
President, CEO
- 11135
35.176 USD
2 years ago
Nov 23, 2022
Sell 79.2 K USD
Khattar Jack A.
President, CEO
- 2259
35.0548 USD
2 years ago
Nov 22, 2022
Sell 21 K USD
Khattar Jack A.
President, CEO
- 600
35.0018 USD
2 years ago
Nov 21, 2022
Sell 18.6 K USD
Khattar Jack A.
President, CEO
- 531
35.0136 USD
2 years ago
Nov 15, 2022
Sell 39 K USD
Khattar Jack A.
President, CEO
- 1115
35.0027 USD
2 years ago
Nov 11, 2022
Sell 238 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 6800
34.9493 USD
2 years ago
Nov 09, 2022
Sell 24.5 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 700
34.9713 USD
2 years ago
Aug 22, 2022
Sell 180 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5000
35.98 USD
2 years ago
Aug 16, 2022
Sell 500 K USD
Khattar Jack A.
President, CEO
- 14690
34.013 USD
2 years ago
Aug 15, 2022
Sell 589 K USD
Khattar Jack A.
President, CEO
- 17302
34.028 USD
2 years ago
Aug 10, 2022
Sell 888 K USD
Khattar Jack A.
President, CEO
- 28437
31.22 USD
2 years ago
Aug 09, 2022
Sell 1.23 M USD
Khattar Jack A.
President, CEO
- 39431
31.15 USD
2 years ago
Aug 08, 2022
Sell 3.39 M USD
Khattar Jack A.
President, CEO
- 107875
31.4 USD
2 years ago
Aug 08, 2022
Sell 322 K USD
Khattar Jack A.
President, CEO
- 10032
32.11 USD
2 years ago
Aug 04, 2022
Sell 165 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 5000
32.98 USD
3 years ago
Apr 13, 2021
Sell 93.7 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 3125
29.9846 USD
3 years ago
Apr 14, 2021
Sell 99.9 K USD
Martin Tami Tillotson
Sr. V.P., Regulatory Affairs
- 3125
31.98 USD
4 years ago
Dec 21, 2020
Sell 1.02 M USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 46347
22.1042 USD
4 years ago
Dec 14, 2020
Sell 1.09 M USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 50000
21.8579 USD
4 years ago
Dec 14, 2020
Sell 80.4 K USD
Schwabe Stefan K.F.
Executive Vice President & CMO
- 3653
22.0007 USD
4 years ago
Nov 09, 2020
Sell 125 K USD
PATRICK GREGORY S
Sr. VP Chief Financial Officer
- 5000
25 USD
4 years ago
Nov 05, 2020
Sell 115 K USD
PATRICK GREGORY S
Sr. VP, CFO
- 5000
23 USD
4 years ago
Oct 15, 2020
Sell 301 K USD
PATRICK GREGORY S
Sr. VP, CFO
- 15000
20.0338 USD
4 years ago
Jul 13, 2020
Sell 22.5 K USD
Hudson Frederick M.
Director
- 920
24.44 USD
4 years ago
May 20, 2020
Sell 375 K USD
PATRICK GREGORY S
Sr.VP, Chief Financial Officer
- 15000
25.0253 USD
4 years ago
May 08, 2020
Sell 347 K USD
PATRICK GREGORY S
Sr VP, Chief Financial Officer
- 15000
23.1356 USD
5 years ago
Aug 23, 2019
Bought 190 K USD
Khattar Jack A.
President, CEO
+ 7200
26.3864 USD
5 years ago
Feb 27, 2019
Sell 831 K USD
PATRICK GREGORY S
Sr VP, Chief Financial Officer
- 20000
41.5325 USD
6 years ago
Jul 02, 2018
Sell 1.98 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 35000
56.6261 USD
6 years ago
Jun 28, 2018
Sell 204 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3402
59.9351 USD
6 years ago
Jun 29, 2018
Sell 263 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 4393
59.9028 USD
6 years ago
Jun 21, 2018
Sell 432 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 7205
60.0032 USD
6 years ago
Jun 18, 2018
Sell 3.26 M USD
Schwabe Stefan K.F.
Executive VP R&D, CMO
- 60000
54.3892 USD
6 years ago
May 15, 2018
Sell 434 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 7500
57.9256 USD
6 years ago
May 10, 2018
Sell 998 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
49.8772 USD
6 years ago
May 11, 2018
Sell 1.04 M USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
52.0279 USD
6 years ago
May 11, 2018
Sell 898 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 16250
55.2334 USD
6 years ago
May 11, 2018
Sell 630 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 10882
57.9 USD
6 years ago
Apr 18, 2018
Sell 471 K USD
Vaughn Victor
Sr. VP of Sales & Marketing
- 10000
47.0617 USD
6 years ago
Apr 19, 2018
Sell 385 K USD
Vaughn Victor
Sr. VP of Sales & Marketing
- 7850
49.0261 USD
6 years ago
Apr 05, 2018
Sell 850 K USD
Vaughn Victor
Sr. VP of Sales and Marketing
- 18750
45.3295 USD
6 years ago
Jan 22, 2018
Sell 961 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
48.0358 USD
7 years ago
Jan 17, 2018
Sell 416 K USD
Vaughn Victor
Sr. VP of Sales
- 9250
45 USD
7 years ago
Jan 17, 2018
Sell 705 K USD
Vaughn Victor
Sr. VP of Sales
- 15000
47.0333 USD
7 years ago
Jan 17, 2018
Sell 900 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 20000
44.975 USD
7 years ago
Jan 12, 2018
Sell 259 K USD
Vaughn Victor
Sr. VP of Sales
- 5750
45.0309 USD
7 years ago
Jan 11, 2018
Sell 2.18 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 50000
43.5629 USD
7 years ago
Jan 09, 2018
Sell 631 K USD
Vaughn Victor
Sr. VP of Sales
- 15000
42.0433 USD
7 years ago
Jan 02, 2018
Sell 2.21 M USD
Vaughn Victor
Sr. VP of Sales
- 55000
40.1147 USD
7 years ago
Sep 08, 2017
Sell 1.15 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 23481
48.8891 USD
7 years ago
Sep 07, 2017
Sell 1.16 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 25000
46.3561 USD
7 years ago
Sep 07, 2017
Sell 72.9 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 1519
48 USD
7 years ago
Sep 07, 2017
Sell 4.43 M USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 95000
46.585 USD
7 years ago
Sep 08, 2017
Sell 249 K USD
Bhatt Padmanabh P.
Sr VP of IP, CSO
- 5000
49.8605 USD
7 years ago
Aug 16, 2017
Sell 168 K USD
Bhatt Padmanabh P.
Sr.VP of IP, CSO
- 3709
45.2291 USD
7 years ago
Jul 12, 2017
Sell 168 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3735
44.9 USD
7 years ago
Jun 23, 2017
Sell 115 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 2556
44.9039 USD
7 years ago
Jun 02, 2017
Sell 399 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 10000
39.8558 USD
7 years ago
May 26, 2017
Sell 89.8 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 2500
35.903 USD
7 years ago
May 24, 2017
Sell 56.3 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 1613
34.9 USD
7 years ago
May 25, 2017
Sell 136 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 3887
34.9 USD
7 years ago
Apr 24, 2017
Sell 1.75 M USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 54000
32.368 USD
7 years ago
Apr 24, 2017
Sell 385 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 11806
32.5904 USD
8 years ago
Sep 16, 2016
Sell 50 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 2000
25 USD
8 years ago
Jul 14, 2016
Sell 74.7 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 3395
22 USD
8 years ago
Apr 11, 2016
Sell 507 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 30762
16.4888 USD
9 years ago
Dec 08, 2015
Sell 142 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 9553
14.9001 USD
9 years ago
Dec 09, 2015
Sell 69.8 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 4685
14.9 USD
9 years ago
Dec 04, 2015
Sell 1.03 M USD
BARRETT M JAMES
Director
- 70990
14.5394 USD
9 years ago
Dec 07, 2015
Sell 1.02 M USD
BARRETT M JAMES
Director
- 71067
14.3835 USD
9 years ago
Dec 08, 2015
Sell 1.05 M USD
BARRETT M JAMES
Director
- 70913
14.7498 USD
9 years ago
Nov 25, 2015
Sell 264 K USD
BARRETT M JAMES
Director
- 16179
16.348 USD
9 years ago
Nov 17, 2015
Sell 835 K USD
BARRETT M JAMES
Director
- 50000
16.7092 USD
9 years ago
Nov 18, 2015
Sell 710 K USD
BARRETT M JAMES
Director
- 43000
16.501 USD
9 years ago
Nov 13, 2015
Sell 1.63 M USD
BARRETT M JAMES
Director
- 100000
16.2561 USD
9 years ago
Nov 16, 2015
Sell 317 K USD
BARRETT M JAMES
Director
- 19650
16.1341 USD
9 years ago
Nov 04, 2015
Sell 99.5 K USD
Bhatt Padmanabh P.
Sr. VP of IP, CSO
- 5000
19.9 USD
9 years ago
Jul 28, 2015
Sell 13.8 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 650
21.21 USD
9 years ago
Jul 28, 2015
Sell 36 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 1700
21.2 USD
9 years ago
Jul 13, 2015
Sell 37.5 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 1950
19.23 USD
9 years ago
Jul 16, 2015
Sell 124 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
- 6217
20 USD
9 years ago
Jul 13, 2015
Sell 37.5 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 1950
19.23 USD
9 years ago
Jun 17, 2015
Sell 1.05 M USD
SANDELL SCOTT D
10 percent owner
- 63085
16.6728 USD
9 years ago
Jun 17, 2015
Sell 421 K USD
SANDELL SCOTT D
10 percent owner
- 24716
17.0261 USD
9 years ago
Jun 17, 2015
Sell 782 K USD
SANDELL SCOTT D
10 percent owner
- 48796
16.0218 USD
9 years ago
Jun 17, 2015
Sell 1.05 M USD
BASKETT FOREST
10 percent owner
- 63085
16.6728 USD
9 years ago
Jun 17, 2015
Sell 782 K USD
BASKETT FOREST
10 percent owner
- 48796
16.0218 USD
9 years ago
Jun 17, 2015
Sell 1.05 M USD
BARRIS PETER J
10 percent owner
- 63085
16.6728 USD
9 years ago
Jun 17, 2015
Sell 782 K USD
BARRIS PETER J
10 percent owner
- 48796
16.0218 USD
9 years ago
Jun 17, 2015
Sell 1.05 M USD
BARRETT M JAMES
director, 10 percent owner:
- 63085
16.6728 USD
9 years ago
Jun 17, 2015
Sell 782 K USD
BARRETT M JAMES
director, 10 percent owner:
- 48796
16.0218 USD
9 years ago
Jun 16, 2015
Sell 929 K USD
BARRETT M JAMES
director, 10 percent owner:
- 55105
16.8527 USD
9 years ago
Jun 16, 2015
Sell 929 K USD
BARRIS PETER J
10 percent owner
- 55105
16.8527 USD
9 years ago
Jun 16, 2015
Sell 929 K USD
BASKETT FOREST
10 percent owner
- 55105
16.8527 USD
9 years ago
Jun 16, 2015
Sell 949 K USD
BASKETT FOREST
10 percent owner
- 56359
16.8458 USD
9 years ago
Jun 16, 2015
Sell 929 K USD
SANDELL SCOTT D
10 percent owner
- 55105
16.8527 USD
9 years ago
Jun 16, 2015
Sell 686 K USD
SANDELL SCOTT D
10 percent owner
- 40332
17.0064 USD
9 years ago
Jun 12, 2015
Sell 37.5 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 2051
18.27 USD
9 years ago
Jun 11, 2015
Sell 22 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 1345
16.32 USD
9 years ago
Jun 11, 2015
Sell 37.6 K USD
Schwabe Stefan K.F.
Executive Vice President R&D
- 2286
16.435 USD
9 years ago
Mar 30, 2015
Sell 80.6 K USD
Bryan Jones W.
VP of Business Development
- 6712
12.0153 USD
9 years ago
Mar 24, 2015
Sell 22.8 K USD
Bryan Jones W.
VP of Business Development
- 1900
12 USD
11 years ago
Aug 19, 2013
Sell 18.8 K USD
Bhatt Padmanabh P.
Sr. VP of IP; CSO
- 2285
8.21 USD
11 years ago
Mar 22, 2013
Bought 84.8 K USD
BIGHAM MICHAEL
Director
+ 15000
5.653 USD
11 years ago
Mar 20, 2013
Bought 52.6 K USD
BIGHAM MICHAEL
Director
+ 10000
5.264 USD
11 years ago
Mar 20, 2013
Bought 26 K USD
BIGHAM MICHAEL
Director
+ 5000
5.195 USD
11 years ago
Mar 20, 2013
Bought 25.9 K USD
BIGHAM MICHAEL
Director
+ 5000
5.172 USD
11 years ago
Mar 21, 2013
Bought 16.5 K USD
SIEBERT JOHN M
Director
+ 3000
5.4999 USD
11 years ago
Mar 15, 2013
Bought 61.5 K USD
Khattar Jack A.
President, CEO
+ 10000
6.1461 USD
11 years ago
Mar 14, 2013
Bought 34.7 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
+ 5000
6.9474 USD
11 years ago
Feb 12, 2013
Sell 833 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 110700
7.5218 USD
11 years ago
Feb 13, 2013
Sell 825 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 108900
7.5757 USD
11 years ago
Feb 12, 2013
Sell 312 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 41483
7.5218 USD
11 years ago
Feb 13, 2013
Sell 311 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 41100
7.5757 USD
12 years ago
Dec 17, 2012
Sell 1.35 M USD
ORBIMED ADVISORS LLC
10 percent owner
- 197815
6.8479 USD
12 years ago
Dec 18, 2012
Sell 708 K USD
ORBIMED ADVISORS LLC
10 percent owner
- 100000
7.0767 USD
12 years ago
Dec 04, 2012
Bought 57 K USD
SIEBERT JOHN M
Director
+ 7000
8.14 USD
12 years ago
May 04, 2012
Bought 5.5 M USD
Abingworth Management LTD
10 percent owner
+ 1100000
5 USD
12 years ago
May 04, 2012
Bought 22 M USD
NEWHALL CHARLES W III
director, 10 percent owner:
+ 4400000
5 USD
12 years ago
May 04, 2012
Bought 22 M USD
BARRETT M JAMES
director, 10 percent owner:
+ 4400000
5 USD
12 years ago
May 04, 2012
Bought 22 M USD
NEW ENTERPRISE ASSOCIATES 11 LP
10 percent owner
+ 4400000
5 USD
12 years ago
May 04, 2012
Bought 3.67 M USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 734128
5 USD
12 years ago
May 04, 2012
Bought 1.37 M USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 274873
5 USD
12 years ago
May 04, 2012
Bought 455 K USD
ORBIMED ADVISORS LLC
director, 10 percent owner:
+ 90999
5 USD
12 years ago
May 04, 2012
Bought 15 K USD
PATRICK GREGORY S
VP, Chief Financial Officer
+ 3000
5 USD
12 years ago
May 04, 2012
Bought 15 K USD
SIEBERT JOHN M
Director
+ 3000
5 USD
12 years ago
May 04, 2012
Bought 25 K USD
Hudson Frederick M.
Director
+ 5000
5 USD
12 years ago
May 04, 2012
Bought 25 K USD
Khattar Jack A.
President, CEO
+ 5000
5 USD
12 years ago
May 04, 2012
Bought 75 K USD
Nuerge William A.
Director
+ 15000
5 USD
12 years ago
May 04, 2012
Bought 3.67 M USD
SHEFFERY MICHAEL B
Director
+ 734128
5 USD
12 years ago
May 04, 2012
Bought 1.37 M USD
SHEFFERY MICHAEL B
Director
+ 274873
5 USD
12 years ago
May 04, 2012
Bought 455 K USD
SHEFFERY MICHAEL B
Director
+ 90999
5 USD
12 years ago
May 04, 2012
Bought 12.5 K USD
Martin Tami Tillotson
VP of Regulatory Affairs
+ 2500
5 USD
7. News
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for Qelbree® (viloxazine extended-release capsules) has been accepted for review by Health Canada. Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). globenewswire.com - 1 month ago
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 12:00 p.m. ET at the Lotte New York Palace in New York City. globenewswire.com - 1 month ago
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 9:30 a.m. GMT (4:30 a.m. EST) at the Waldorf Hilton in London, United Kingdom. globenewswire.com - 2 months ago
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth Supernus Pharmaceuticals recently posted better-than-expected Q3 results, and management also revised FY2024 guidance upward. The ADHD drug Qelbree, which was approved in 2021, is powering revenue growth, and reduced costs are benefiting the bottom line. The company also has a pristine balance sheet with just over $400 million in cash and marketable securities. seekingalpha.com - 2 months ago
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Peter Vozzo – Investor Relations-ICR Healthcare Jack Khattar – Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Andrew Tsai – Jefferies Stacy Ku – TD Cowen David Amsellem – Piper Sandler Operator Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com - 2 months ago
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to loss of $0.29 per share a year ago. zacks.com - 2 months ago
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder (MDD). globenewswire.com - 2 months ago
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes on Monday, November 4, 2024. globenewswire.com - 2 months ago
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression Company to host webcast today at 4:30 p.m. ET to discuss the topline data Topline results from Phase 2b randomized double-blind placebo-controlled study of SPN-820 in adults with treatment-resistant depression expected first-half 2025 ROCKVILLE, Md. globenewswire.com - 3 months ago
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, October 17, 2024, at 4:30 p.m. ET to review data from the open-label Phase 2a study of SPN-820 for the treatment of major depressive disorder. globenewswire.com - 3 months ago
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree ROCKVILLE, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- In a continued collaboration with Supernus Pharmaceuticals, actress, author, podcaster, late-night host, and mom, Busy Philipps, is speaking up this fall about her ongoing journey with attention-deficit/hyperactivity disorder (ADHD), bringing awareness to the often-overlooked symptoms of the condition in women and Qelbree, a non-stimulant ADHD treatment that has benefitted her. globenewswire.com - 3 months ago
8. Profile Summary

Supernus Pharmaceuticals, Inc. SUPN

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 2.08 B
Dividend Yield 0.00%
Description Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Contact 9715 Key West Avenue, Rockville, MD, 20850 https://www.supernus.com
IPO Date May 1, 2012
Employees 652
Officers Dr. Todd Horich M.B.A., Ph.D. Senior Vice President of Marketing, Commercial Operations & Market Access Mr. Jack A. Khattar M.B.A. Founder, President, Chief Executive Officer, Secretary & Director Mr. Frank Mottola Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs Dr. Jonathan Rubin M.B.A., M.D. Senior Vice President of Research & Development and Chief Medical Officer Mr. Taylor Raiford Senior Vice President of Sales Mr. Kevin T. Anderson Esq. Compliance Officer Dr. Bryan A. Roecklein Ph.D. Senior Vice President of Corporate Development Mr. Jeff Bozick Senior Vice President of Supply Chain Mr. Timothy C. Dec Senior Vice President & Chief Financial Officer Dr. Padmanabh P. Bhatt Ph.D. Chief Scientific Officer & Senior Vice President of Intellectual Property